Sign In
Buy EXEL
$56.04
-0.460 (-0.81%)
At Close: Jul 13, 2026
3 Under-the-Radar Stocks to Buy and Hold
02:30pm, Friday, 10'th Jul 2026
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
03:26pm, Thursday, 09'th Jul 2026
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Stocks Look Shaky, But This Sector is Booming (Biotech)
02:06pm, Thursday, 09'th Jul 2026
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:46am, Thursday, 09'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 08'th Jul 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 08'th Jul 2026
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:40am, Monday, 06'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:45am, Tuesday, 23'rd Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Friday, 19'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:51am, Thursday, 18'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis Hits High on Growing Sales, Institutional Inflows
08:25am, Wednesday, 10'th Jun 2026
Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:42pm, Tuesday, 09'th Jun 2026
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 04'th Jun 2026
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
